Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:healthcare_organization
|
| gptkbp:accessibility |
improving in low-income countries
|
| gptkbp:activities |
induces immune response against HPV
|
| gptkbp:advocates_for |
required prior to vaccination
|
| gptkbp:age |
9 to 25 years
|
| gptkbp:allows |
does not protect against all HPV types
|
| gptkbp:antagonist |
A S04 adjuvant system
|
| gptkbp:approves |
gptkb:2007
gptkb:European_Medicines_Agency gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:associated_with |
reduction in HPV-related diseases
|
| gptkbp:clinical_trial |
demonstrated efficacy in preventing cervical cancer
part of routine vaccination programs |
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:curriculum |
available for healthcare providers and patients
|
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
gptkb:3
suspension for injection |
| gptkbp:events |
recommended after vaccination series
|
| gptkbp:healthcare |
educate patients about benefits
reduces incidence of cervical cancer |
| https://www.w3.org/2000/01/rdf-schema#label |
Cervarix
|
| gptkbp:invention |
patented
|
| gptkbp:is_used_for |
prevention of cervical cancer
|
| gptkbp:is_vulnerable_to |
varies by region
managed by health authorities 0, 1, and 6 months bivalent vaccine collaborations with NG Os and health organizations high efficacy against HPV 16 and 18 includes long-term effectiveness studies updated based on new research findings show significant reduction in cervical cancer rates |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:market |
conducted to monitor safety
|
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:provides_information_on |
follow national immunization schedules
|
| gptkbp:public_awareness |
important for vaccination uptake
implemented in various countries |
| gptkbp:receives_funding_from |
government and private sectors
|
| gptkbp:research_and_development |
ongoing studies for broader HPV coverage
|
| gptkbp:side_effect |
fatigue
headache nausea fever pain at injection site |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:suitable_for |
pregnant women
immunocompromised individuals |
| gptkbp:target_audience |
females
|
| gptkbp:targets |
gptkb:human_papillomavirus_(HPV)_types_16_and_18
|